TREVENA INC (TRVN)

US89532E2081 - Common Stock

2.5  -2.11 (-45.71%)

After market: 2.39 -0.11 (-4.4%)

Fundamental Rating

2

Taking everything into account, TRVN scores 2 out of 10 in our fundamental rating. TRVN was compared to 568 industry peers in the Biotechnology industry. TRVN may be in some trouble as it scores bad on both profitability and health. TRVN is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRVN has reported negative net income.
In the past year TRVN has reported a negative cash flow from operations.
TRVN had negative earnings in each of the past 5 years.
In the past 5 years TRVN always reported negative operating cash flow.

1.2 Ratios

TRVN has a Return On Assets of -264.95%. This is amonst the worse of the industry: TRVN underperforms 94.16% of its industry peers.
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROIC N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 44.36%, TRVN is in the better half of the industry, outperforming 78.76% of the companies in the same industry.
TRVN's Gross Margin has declined in the last couple of years.
TRVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

TRVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRVN has less shares outstanding
The number of shares outstanding for TRVN has been reduced compared to 5 years ago.
The debt/assets ratio for TRVN is higher compared to a year ago.

2.2 Solvency

TRVN has an Altman-Z score of -44.49. This is a bad value and indicates that TRVN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -44.49, TRVN is not doing good in the industry: 93.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.49
ROIC/WACCN/A
WACC3.98%

2.3 Liquidity

TRVN has a Current Ratio of 3.46. This indicates that TRVN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.46, TRVN is not doing good in the industry: 60.88% of the companies in the same industry are doing better.
A Quick Ratio of 3.46 indicates that TRVN has no problem at all paying its short term obligations.
TRVN's Quick ratio of 3.46 is in line compared to the rest of the industry. TRVN outperforms 41.06% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46

More info and screens

5

3. Growth

3.1 Past

TRVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -265.62%.
TRVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.93%.
TRVN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.42% yearly.
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%

3.2 Future

Based on estimates for the next years, TRVN will show a very strong growth in Earnings Per Share. The EPS will grow by 49.93% on average per year.
TRVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 198.34% yearly.
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as TRVN's earnings are expected to decrease with -100.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVENA INC

NASDAQ:TRVN (10/7/2024, 8:23:32 PM)

After market: 2.39 -0.11 (-4.4%)

2.5

-2.11 (-45.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-12 2024-11-12/bmo
Inst Owners4.42%
Inst Owner Change-95.5%
Ins Owners1065.78%
Ins Owner Change-0.04%
Market Cap2.13M
Analysts82.5
Price Target102 (3980%)
Short Float %3.72%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.61%
Min EPS beat(2)24.91%
Max EPS beat(2)44.32%
EPS beat(4)2
Avg EPS beat(4)-95.1%
Min EPS beat(4)-275.05%
Max EPS beat(4)44.32%
EPS beat(8)5
Avg EPS beat(8)-33.77%
EPS beat(12)8
Avg EPS beat(12)-19.49%
EPS beat(16)10
Avg EPS beat(16)-15.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1998.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-2027.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1500%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-16.38
EYN/A
EPS(NY)-20.25
Fwd EYN/A
FCF(TTM)-37.1
FCFYN/A
OCF(TTM)-37.08
OCFYN/A
SpS4.29
BVpS-22.3
TBVpS-22.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.36%
FCFM N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.16%
Cap/Sales 0.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -44.49
F-Score3
WACC3.98%
ROIC/WACCN/A
Cap/Depr(3y)8.27%
Cap/Depr(5y)6.21%
Cap/Sales(3y)3.99%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%
EBIT growth 1Y-46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.58%
OCF growth 3YN/A
OCF growth 5YN/A